Candel Therapeutics, Inc. (CADL): Earnings growth forecast for next year
Geopolitical fragmentation is severely hindering international cancer therapy trials by disrupting the delivery of biomaterials. This earnings per share (EPS) forecast chart illustrates the market reaction to these risks, where -16.90 characterizes this valuation parameter. The balance sheet stability of Candel Therapeutics (CADL) is supported by grants, while the strategy for expanding the viral drug portfolio relies on preparations for Phase III trials.
Analytical breakdowns for Candel Therapeutics Inc. (CADL)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- company liabilities and liquidity data:
Total Debt to Capital Candel Therapeutics|CADL - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Candel Therapeutics Inc.|CADL - Company Cumulative Debt|Debt to Book Capitalization Ratio Candel Therapeutics Inc.|CADL - Company Long-Term Debt|Company Current Liabilities Candel Therapeutics|Quick Liquidity Indicator candeltx.com
- earnings and valuation multiples information:
CADL - Profit After Payment of Taxes|Projected Future Earnings Candel Therapeutics|CADL - Company Value to Net Income|Forward P/E Multiple Candel Therapeutics Inc.|CADL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Candel|CADL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Candel Therapeutics|CADL - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months candeltx.com|CADL - Earnings per share trend in current year|Earnings growth forecast for next year Candel Therapeutics
- revenue and sales proceeds data:
Fundamental company analysis:CADL, Candel Therapeutics, Inc.
This indicator reflects the aggregated analyst consensus regarding the growth rate of net earnings per share. The calculation is based on the continuous updating of market expectations, transforming subjective estimates into an objective time series. By analyzing the projected earnings per share trend for the coming year, an investor assesses the degree of certainty regarding future cash flows. For Candel Therapeutics (CADL), this metric depends directly on the efficiency of R&D investments in the development of breakthrough oncolytic viruses.
Key competitors
ONC (BeiGene Ltd) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Therapeutics HALO|Net earnings per share growth forecast for next year Revolution Medicines, Inc. (RVMD)|Earnings growth forecast for next year Ascentage Pharma Group International (AAPG)|Earnings growth forecast for next year CGON (CG Oncology Inc)|Expected earnings per share trend next year URGN|bicara.com - Earnings growth forecast for next year|Expected earnings per share trend next year PSNL (personalis.com)|Erasca Inc (ERAS) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Delcath Systems|YMAB (YmAbs) - Earnings growth forecast for next year|AURA: Expected earnings per share trend next year|Earnings growth forecast for next year ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Expected earnings per share trend next year|Earnings growth forecast for next year ACTU (Actuate Therapeutics Inc)|Expected earnings per share trend next year CTOR|tuhurabio.com - Earnings growth forecast for next year|Expected earnings per share trend next year TARA (Protara Therapeutics)|Fate Therapeutics, Inc. (FATE) - Net earnings per share growth forecast for next year|WHWK - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year tscan.com|CSBR: Expected earnings per share trend next year|Net earnings per share growth forecast for next year XBiotech USA (XBIT)|CVM: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year ostherapies.com OSTX|Projected earnings per share increase next year RADX (Radiopharm Theranostics Limited)|Artiva - Earnings growth forecast for next year|ANL: Net earnings per share growth forecast for next year|VERU: Earnings growth forecast for next year|Net earnings per share change forecast for next year TPST (Tempest Tx)|XLO (Xilio Therapeutics) - Earnings growth forecast for next year|Expected net earnings per share growth next year renovarobio.com RENB|Net earnings per share growth forecast for next year muraloncology.com (MURA)|Projected earnings per share increase next year KAPA|Earnings growth forecast for next year OKUR (onkuretherapeutics.com)|Projected earnings per share increase next year GDTC (CytoMed)|Curis - Earnings growth forecast for next year|APLM: Net earnings per share growth forecast for next year|Tharimmune (THAR) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Advanced Biomed Inc.|GNPX (Genprex Inc) - Earnings growth forecast for next year|Calidi Biotherapeutics (CLDI) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year SBFM|Net earnings per share growth forecast for next year XBIO (Xenetic Biosciences, Inc.)|Earnings growth forecast for next year SLRX (salariuspharma.com)|PPBT - Expected earnings per share growth for next year|AONC - Net earnings per share growth forecast for next year|Expected earnings per share trend next year BGNE (BeOne Medicines)|CKPT: Earnings growth forecast for next year|Elevation Oncology Inc. (ELEV) - Earnings growth forecast for next year|ICAD (iCAD) - Earnings growth forecast for next year|Earnings growth forecast for next year ikenaoncology.com|Earnings growth forecast for next year NTBL|Earnings growth forecast for next year Viracta Therapeutics Inc. (VIRX)|Net earnings per share growth forecast for next year MorphoSys Inc MOR|Expected earnings per share trend next year NAYA|AAPGV: Expected earnings per share growth for next year
